A citation-based method for searching scientific literature

Martin R Stockler, Felix Hilpert, Michael Friedlander, Madeleine T King, Lari Wenzel, Chee Khoon Lee, Florence Joly, Nikolaus de Gregorio, José Angel Arranz, Mansoor Raza Mirza, Roberto Sorio, Ulrich Freudensprung, Vesna Sneller, Gill Hales, Eric Pujade-Lauraine. J Clin Oncol 2014
Times Cited: 110







List of co-cited articles
842 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Eric Pujade-Lauraine, Felix Hilpert, Béatrice Weber, Alexander Reuss, Andres Poveda, Gunnar Kristensen, Roberto Sorio, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias,[...]. J Clin Oncol 2014
766
76

Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Robert A Burger, Mark F Brady, Michael A Bookman, Gini F Fleming, Bradley J Monk, Helen Huang, Robert S Mannel, Howard D Homesley, Jeffrey Fowler, Benjamin E Greer,[...]. N Engl J Med 2011
44

A phase 3 trial of bevacizumab in ovarian cancer.
Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder,[...]. N Engl J Med 2011
43

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012
781
41

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
Joyce F Liu, William T Barry, Michael Birrer, Jung-Min Lee, Ronald J Buckanovich, Gini F Fleming, Bj Rimel, Mary K Buss, Sreenivasa Nattam, Jean Hurteau,[...]. Lancet Oncol 2014
356
21

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.
Bradley J Monk, Andrés Poveda, Ignace Vergote, Francesco Raspagliesi, Keiichi Fujiwara, Duk-Soo Bae, Ana Oaknin, Isabelle Ray-Coquard, Diane M Provencher, Beth Y Karlan,[...]. Lancet Oncol 2014
187
20

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Lancet Oncol 2014
850
20

Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. N Engl J Med 2012
19


Incorporation of pazopanib in maintenance therapy of ovarian cancer.
Andreas du Bois, Anne Floquet, Jae-Weon Kim, Joern Rau, Josep M del Campo, Michael Friedlander, Sandro Pignata, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo,[...]. J Clin Oncol 2014
204
18

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.
Amit M Oza, Adrian D Cook, Jacobus Pfisterer, Andrew Embleton, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes,[...]. Lancet Oncol 2015
364
17


Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.
A N Gordon, J T Fleagle, D Guthrie, D E Parkin, M E Gore, A J Lacave. J Clin Oncol 2001
873
16

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
M K B Parmar, J A Ledermann, N Colombo, A du Bois, J-F Delaloye, G B Kristensen, S Wheeler, A M Swart, W Qian, V Torri,[...]. Lancet 2003
788
16

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
Stephen A Cannistra, Ursula A Matulonis, Richard T Penson, Julie Hambleton, Jakob Dupont, Howard Mackey, Jeffrey Douglas, Robert A Burger, Deborah Armstrong, Robert Wenham,[...]. J Clin Oncol 2007
536
15

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Bella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, M William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M Stemmer, Ayala Hubert,[...]. J Clin Oncol 2015
998
15

Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.
Andres M Poveda, Frédéric Selle, Felix Hilpert, Alexander Reuss, Antonella Savarese, Ignace Vergote, Petronella Witteveen, Aristotelis Bamias, Nana Scotto, Lada Mitchell,[...]. J Clin Oncol 2015
93
16

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
Jacobus Pfisterer, Marie Plante, Ignace Vergote, Andreas du Bois, Hal Hirte, Angel J Lacave, Uwe Wagner, Anne Stähle, Gavin Stuart, Rainer Kimmig,[...]. J Clin Oncol 2006
488
15

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse.
Eric Pujade-Lauraine, Uwe Wagner, Elisabeth Aavall-Lundqvist, Val Gebski, Mark Heywood, Paul A Vasey, Birgit Volgger, Ignace Vergote, Sandro Pignata, Annamaria Ferrero,[...]. J Clin Oncol 2010
342
14

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
14

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
Robert A Burger, Michael W Sill, Bradley J Monk, Benjamin E Greer, Joel I Sorosky. J Clin Oncol 2007
569
13

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial.
Dan Stark, Matthew Nankivell, Eric Pujade-Lauraine, Gunnar Kristensen, Lorraine Elit, Martin Stockler, Felix Hilpert, Andrés Cervantes, Julia Brown, Anne Lanceley,[...]. Lancet Oncol 2013
86
15

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.
David G Mutch, Mauro Orlando, Tiana Goss, Michael G Teneriello, Alan N Gordon, Scott D McMeekin, Yanping Wang, Dennis R Scribner, Martin Marciniack, R Wendel Naumann,[...]. J Clin Oncol 2007
266
13

Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Robert L Coleman, Mark F Brady, Thomas J Herzog, Paul Sabbatini, Deborah K Armstrong, Joan L Walker, Byoung-Gie Kim, Keiichi Fujiwara, Krishnansu S Tewari, David M O'Malley,[...]. Lancet Oncol 2017
243
13

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease.
M K Wilson, E Pujade-Lauraine, D Aoki, M R Mirza, D Lorusso, A M Oza, A du Bois, I Vergote, A Reuss, M Bacon,[...]. Ann Oncol 2017
107
13

Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study.
Bradley J Monk, Helen Q Huang, Robert A Burger, Robert S Mannel, Howard D Homesley, Jeffrey Fowler, Benjamin E Greer, Matthew Boente, Sharon X Liang, Lari Wenzel. Gynecol Oncol 2013
46
26

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
Bradley J Monk, Thomas J Herzog, Stanley B Kaye, Carolyn N Krasner, Jan B Vermorken, Franco M Muggia, Eric Pujade-Lauraine, Alla S Lisyanskaya, Anatoly N Makhson, Janusz Rolski,[...]. J Clin Oncol 2010
267
12

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Amit M Oza, David Cibula, Ana Oaknin Benzaquen, Christopher Poole, Ron H J Mathijssen, Gabe S Sonke, Nicoletta Colombo, Jiří Špaček, Peter Vuylsteke, Holger Hirte,[...]. Lancet Oncol 2015
339
12

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
Kathryn Alsop, Sian Fereday, Cliff Meldrum, Anna deFazio, Catherine Emmanuel, Joshy George, Alexander Dobrovic, Michael J Birrer, Penelope M Webb, Colin Stewart,[...]. J Clin Oncol 2012
680
12

Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
Jonathan A Ledermann, Andrew C Embleton, Fharat Raja, Timothy J Perren, Gordon C Jayson, Gordon J S Rustin, Stan B Kaye, Hal Hirte, Elizabeth Eisenhauer, Michelle Vaughan,[...]. Lancet 2016
129
12

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Walter H Gotlieb, Frederic Amant, Suresh Advani, Chanchal Goswami, Hal Hirte, Diane Provencher, Naresh Somani, S Diane Yamada, Jean-Francois Tamby, Ignace Vergote. Lancet Oncol 2012
97
11

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
Ursula A Matulonis, Suzanne Berlin, Percy Ivy, Karin Tyburski, Carolyn Krasner, Corrine Zarwan, Anna Berkenblit, Susana Campos, Neil Horowitz, Stephen A Cannistra,[...]. J Clin Oncol 2009
200
11

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
M Markman, R Rothman, T Hakes, B Reichman, W Hoskins, S Rubin, W Jones, L Almadrones, J L Lewis. J Clin Oncol 1991
652
11

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial.
Gordon J S Rustin, Maria E L van der Burg, Clare L Griffin, David Guthrie, Alan Lamont, Gordon C Jayson, Gunnar Kristensen, César Mediola, Corneel Coens, Wendi Qian,[...]. Lancet 2010
301
11

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer.
Michael Friedlander, Kenneth C Hancock, Danny Rischin, Mark J Messing, Claude A Stringer, Gemma M Matthys, Bo Ma, Jeffrey P Hodge, Joanne J Lager. Gynecol Oncol 2010
166
10

Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial.
Sandro Pignata, Domenica Lorusso, Giovanni Scambia, Daniela Sambataro, Stefano Tamberi, Saverio Cinieri, Anna M Mosconi, Michele Orditura, Alba A Brandes, Valentina Arcangeli,[...]. Lancet Oncol 2015
86
11

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
Stan B Kaye, Jan Lubinski, Ursula Matulonis, Joo Ern Ang, Charlie Gourley, Beth Y Karlan, Amit Amnon, Katherine M Bell-McGuinn, Lee-May Chen, Michael Friedlander,[...]. J Clin Oncol 2012
328
10

Clinical trials in recurrent ovarian cancer.
Michael Friedlander, Edward Trimble, Anna Tinker, David Alberts, Elisabeth Avall-Lundqvist, Mark Brady, Philipp Harter, Sandro Pignata, Eric Pujade-Lauraine, Jalid Sehouli,[...]. Int J Gynecol Cancer 2011
126
10

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
Deborah K Armstrong, Brian Bundy, Lari Wenzel, Helen Q Huang, Rebecca Baergen, Shashikant Lele, Larry J Copeland, Joan L Walker, Robert A Burger. N Engl J Med 2006
10

Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Junzo Hamanishi, Masaki Mandai, Takafumi Ikeda, Manabu Minami, Atsushi Kawaguchi, Toshinori Murayama, Masashi Kanai, Yukiko Mori, Shigemi Matsumoto, Shunsuke Chikuma,[...]. J Clin Oncol 2015
606
10

Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata,[...]. Lancet Oncol 2017
705
10

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.
Noriyuki Katsumata, Makoto Yasuda, Fumiaki Takahashi, Seiji Isonishi, Toshiko Jobo, Daisuke Aoki, Hiroshi Tsuda, Toru Sugiyama, Shoji Kodama, Eizo Kimura,[...]. Lancet 2009
486
9

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.
N K Aaronson, S Ahmedzai, B Bergman, M Bullinger, A Cull, N J Duez, A Filiberti, H Flechtner, S B Fleishman, J C de Haes. J Natl Cancer Inst 1993
9

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Kathryn P Pennington, Tom Walsh, Maria I Harrell, Ming K Lee, Christopher C Pennil, Mara H Rendi, Anne Thornton, Barbara M Norquist, Silvia Casadei, Alexander S Nord,[...]. Clin Cancer Res 2014
496
9

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Karen A Gelmon, Marc Tischkowitz, Helen Mackay, Kenneth Swenerton, André Robidoux, Katia Tonkin, Hal Hirte, David Huntsman, Mark Clemons, Blake Gilks,[...]. Lancet Oncol 2011
767
9


2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference.
Gavin C E Stuart, Henry Kitchener, Monica Bacon, Andreas duBois, Michael Friedlander, Jonathan Ledermann, Christian Marth, Tate Thigpen, Edward Trimble. Int J Gynecol Cancer 2011
273
9

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Sandro Pignata, Giovanni Scambia, Dionyssios Katsaros, Ciro Gallo, Eric Pujade-Lauraine, Sabino De Placido, Alessandra Bologna, Beatrice Weber, Francesco Raspagliesi, Pierluigi Benedetti Panici,[...]. Lancet Oncol 2014
206
9

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.
Robert F Ozols, Brian N Bundy, Benjamin E Greer, Jeffrey M Fowler, Daniel Clarke-Pearson, Robert A Burger, Robert S Mannel, Koen DeGeest, Ellen M Hartenbach, Rebecca Baergen. J Clin Oncol 2003
9

Whole-genome characterization of chemoresistant ovarian cancer.
Ann-Marie Patch, Elizabeth L Christie, Dariush Etemadmoghadam, Dale W Garsed, Joshy George, Sian Fereday, Katia Nones, Prue Cowin, Kathryn Alsop, Peter J Bailey,[...]. Nature 2015
740
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.